Stockscreener 앱 받기
62.03
11.99%
6.64
시장 영업 전:
62.48
0.45
+0.73%
전일 마감가:
$55.39
열려 있는:
$58.45
하루 거래량:
1.59M
Relative Volume:
2.15
시가총액:
$2.68B
수익:
$4.85M
순이익/손실:
$-114.75M
주가수익비율:
-19.09
EPS:
-3.25
순현금흐름:
$-100.36M
1주 성능:
+19.59%
1개월 성능:
+28.88%
6개월 성능:
+151.54%
1년 성능:
+212.34%
1일 변동 폭
$58.20
$64.67
1주일 범위
$51.00
$64.67
52주 변동 폭
$13.37
$64.67
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
명칭
Dianthus Therapeutics Inc
전화
929-999-4055
주소
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
62.03 | 2.39B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 개시 | Truist | Buy |
| 2025-07-02 | 개시 | William Blair | Outperform |
| 2024-12-20 | 개시 | TD Cowen | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-26 | 개시 | Robert W. Baird | Outperform |
| 2024-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-16 | 개시 | H.C. Wainwright | Buy |
| 2024-02-15 | 개시 | Stifel | Buy |
| 2023-12-26 | 개시 | Jefferies | Buy |
| 2023-11-22 | 개시 | Wedbush | Outperform |
| 2023-10-30 | 개시 | Guggenheim | Buy |
| 2023-09-28 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-08-20 | 재개 | Goldman | Neutral |
| 2021-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-22 | 재확인 | B. Riley Securities | Buy |
| 2021-06-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-18 | 개시 | B. Riley Securities | Buy |
| 2021-01-07 | 개시 | Mizuho | Buy |
| 2020-06-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-03-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-03-15 | 개시 | Raymond James | Outperform |
모두보기
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Dianthus Therapeutics stock hits 52-week high at 58.45 USD - Investing.com
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighShould You Buy? - MarketBeat
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views - Benzinga
Guggenheim raises Dianthus Therapeutics stock price target to $200 on autoimmune potential - Investing.com Canada
Dianthus Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
DNTH: Accelerated CIDP and MMN trials target 2024 milestones with patient-friendly, differentiated protocols - TradingView
DNTH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Tuesday - Defense World
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: A 37% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Dianthus Therapeutics (DNTH) stock rises ahead of TD Cowen conference; what investors watch next - TechStock²
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference - Bitget
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 6.1%Time to Buy? - MarketBeat
Patient Square Capital LP Makes New Investment in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (DNTH): Analyst Consensus Points to a Promising 46.82% Upside Potential - DirectorsTalk Interviews
Ideas Watch: Whats the RSI of Dianthus Therapeutics Inc stockOil Prices & High Return Trade Guides - baoquankhu1.vn
RA Capital discloses 6.0% Dianthus Therapeutics (DNTH) ownership stake - Stock Titan
Point72 boosts Dianthus Therapeutics (DNTH) stake to 6.9% passive ownership - Stock Titan
Transcript : Dianthus Therapeutics, Inc. Presents at Guggenheim Securities Emerging Outlook - marketscreener.com
Assessing Dianthus Therapeutics (DNTH) Valuation After A Strong Year And Recent Share Price Pullback - Sahm
Will Dianthus Therapeutics Inc. (87E) stock beat international competitionPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans - MarketBeat
Will Dianthus Therapeutics Inc. stock go up in YEARPortfolio Value Summary & Verified Short-Term Plans - mfd.ru
DNTH: Key 2026 clinical milestones and strong commercial outlook drive optimism for pipeline success - TradingView
DNTH: Pivotal trial readouts and strong financials position the pipeline for major commercial impact - TradingView
What 4 Analyst Ratings Have To Say About Dianthus Therapeutics - Benzinga
Can Dianthus Therapeutics Inc. deliver alpha2025 Winners & Losers & Verified Momentum Stock Alerts - mfd.ru
Wedbush Boosts Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $55.00 - MarketBeat
Is Dianthus Therapeutics Inc. a turnaround storyBear Alert & Verified Momentum Stock Alerts - mfd.ru
Candriam S.C.A. Purchases 60,852 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
How Investors Are Reacting To Dianthus Therapeutics (DNTH) US$600 Million Universal Shelf Registration - simplywall.st
Assessing Dianthus Therapeutics (DNTH) Valuation After New US$600m Shelf Registration Filing - Sahm
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - 富途牛牛
Dianthus CEO joins analyst-led fireside chat at Guggenheim summit - Stock Titan
Dianthus Therapeutics (DNTH) Price Target Increased by 10.51% to 75.99 - Nasdaq
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update - MarketBeat
Jefferies Financial Group Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Given New $81.00 Price Target at Jefferies Financial Group - MarketBeat
Will Dianthus Therapeutics Inc. stock keep outperforming rivalsJuly 2025 EndofMonth & Weekly Top Stock Performers List - mfd.ru
Biotech Stocks To Follow Today – January 30th - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biotech Stocks To Follow TodayJanuary 30th - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 54.05 USD By Investing.com - Investing.com India
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: A Biotech Gem with 21.98% Upside Potential - DirectorsTalk Interviews
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 54.05 USD - Investing.com
Oppenheimer Boosts Price Target on Dianthus Therapeutics to $125 From $62, Keeps Outperform Rating - marketscreener.com
Oppenheimer raises Dianthus Therapeutics stock price target to $125 from $62 - Investing.com Canada
Dianthus Therapeutics Inc (DNTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):